Undifferentiated carcinoma of the parotid gland is a poor-prognosis lesion. Results in unresectable lesions, treated with radiotherapy alone, are very disappointing.
Methods
Six patients with T3-4 N0-1 inoperable lesions were treated with conventional radiotherapy (64-70 Gy, 2 Gy per fraction 5 times a week) and concomitant cisplatin (100 mg/m2, days 1, 22 and 43). Four weeks after radiotherapy, adjuvant chemotherapy (cisplatin, 80 mg/m2, day 1, + VP16, 100 mg/m2, days 1, 3 and 5, q = 3 weeks, for 3 cycles) was given.
Results
A median dose of 66 Gy (range, 64-70 Gy) was delivered, and all patients recived 3 courses of cisplatin during radiotherapy. Five of 6 patients recived all three chemotherapeutic adjuvant courses. Two months after the end of treatment, 3 CR (50%), 2 PR (33%) and 1 NC (16%) was observed. Median CR and PR duration was 26+ and 10 months, respectively. Median overall survival was 18 months. No severe acute or late toxicity was observed.
Conclusions
Concomitant chemoradiotherapy followed by adjuvant chemotherapy in advanced unresectable undifferentiated parotid carcinoma is feasibile and well tolerated. The high percentage of long-lasting CR is encouraging.
GuillamondeguiO.M., ByersR.M., LunaM.A., ChiminazzoH., JesseR.H., FletcherGH: Aggressive surgery in treatment for parotid cancer. The role of adjunctive postoperative radiotherapy. Am J Roentgenol Radium Ther Nucl Med, 123: 49–54, 1975.
3.
MillionR.R., CassisiN.J., MancusoAA;Major salivary gland tumors. In: Management of head and neck cancer: multidisciplinary approach, MillionRR, CassisiNJ (Eds), Lippincott, Philadelphia, pp 711–735, 1994.
4.
SimpsonJR: Salivary glands. In: Principle and practice of radiation oncology, PerezCA, BradyLW (Eds), Lippincott, Philadelphia, pp 657–671, 1992.
5.
RossmanKJ: The role of radiation therapy in treatment of parotid carcinoma. Am J Roentgenol Radium Ther Nucl Med, 123: 492–499, 1975.
6.
ShidniaH., HornbackN.B., HamakerR., LingemanR: Carcinoma of the major salivary glands. Cancer, 45: 693–697, 1980.
7.
BuchholzT.A., LaramoreG.E., GriffinB.R., KohW.J., GriffinTW: The role of fast neutron radiation therapy in the management of advanced salivary gland malignant neoplasms. Cancer, 69: 2779–2788, 1992.
8.
CatterallM., ErringtonRD: The implications of improved treatment of malignant salivary gland tumors by fast neutron radiotherapy. Int J Radiat Oncol Biol Phys, 13: 1313–1318, 1987.
9.
KohW.J., LaramoreG., GriffinT., RusselK., GriffinB., ParkerR., LawrenceD., PajakTF: Fast neutron radiation for inoperable and recurrent salivary gland cancers. Am J Clin Oncol, 12: 316–319, 1989.
10.
LaramoreG.E., KrallJ.M., GriffinT.W., DuncanW., RichterM.P., SarojaK.R., MaorM.H., DavisLW: Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized trial. Int J Radiat Oncol Biol Phys, 27: 235–240, 1993.
11.
ArmstrongJ.G., HarrisonL.B., SpiroRH: Brachytherapy for malignant tumors of salivary gland origin. Endocurie, Hyper-therm Oncol, 6: 19–23, 1990.
12.
FuK.K., LeibelS.A., LevineM.L., FriedlanderL.M., BolesR., PhillipsTL: Carcinoma of the major and minor salivary glands. Analysis of treatment results and sites and causes of failure. Cancer, 40: 2882–2890, 1977.
13.
GoffinetDR: Salivary neoplams-Radiation therapy. Proceedings 4th Int Conference on Head and Neck Cancer, Toronto, pp 726–732, 1996.
14.
WangC.C., GoodmanM: Photon irradiation of unresectable carcinomas of salivary glands. Int J Radiat Oncol Biol Phys, 21: 569–576, 1991.
15.
AiroldiM., BrandoV., GiordanoC., GabrieleP., BussiM., CortesinaG: Chemotherapy for recurrent salivary gland malignancies: experience of the ENT Department of Turin University. ORL, 56: 105–111, 1994.
16.
AiroldiM., PedaniF., BrandoV., GabrieleP., GiordanoC: Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. Tumori, 75: 252–256, 1989.
AiroldiM., BertettoO., GabrieleP., BussiM., SuccoG., GabrieleA.M., BummaC: Cisplatin + vinorelbine vs vinorelbine alone in recurrent salivary gland malignancies: a randomized trial. Proc Am Soc Clin Oncol, 17: 383, 1998.
20.
AdelsteinD., AdamsG.L., LiY., WagnaerH., KishJ.A., EnsleyJ.F., SchullerD.E., ForastiereAA: A phase III comparison of standard radiation therapy versus RT plus concurrent cisplatin versus split-course RT plus concurrent DDP and 5-fluorouracil in patients with unresectable squamous cell head and neck cancer: an Intergroup Study. Proc Am Soc Clin Oncol, 19: 411, 2000.
21.
Al-SarrafM., LeBlancM., GiriP.S.G., FuK., CooperJ., VuongT., ForastiereA., AdamsG., SakrW., SchullerD., EnsleyJ: Chemo-radiotherapy vs radiotherapy in patients with advanced nasopharyngeal cancer: Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) phase III study: progress report. Proc Am Soc Clin Oncol, 17: 385, 1998.
22.
BourhisJ., PignonJ.P., Designe'L., LuboinskiM., GuerinS., DomengeC: Meta-analysis of chemotherapy in head and neck cancer: loco-regional treatment vs same treatment + chemotherapy. Proc Am Soc Clin Oncol, 17: 386, 1998.
23.
GabrieleP., AmichettiM., OrecchiaR., ValdagniR: Hyperthermia and radiation therapy for inoperable or recurrent parotid carcinoma. Cancer, 75: 908–913, 1995.
24.
CreaganE.T., SchyttA.J., RichardsonR.L., SchaidDJ: Phase II trial of VP-16, bleomycin, and cisplatin in patients with advanced nonsquamous cell head and neck neoplasms. Am J Clin Oncol, 16: 291–294, 1993.
25.
JohnsonJ.T., WagnerR.L., MyersEN: A long-term assessment of adjuvant chemotherapy on outcome of patients with extracapsular spread of cervical metastases from squamous carcinoma of the head and neck. Cancer, 77: 181–185, 1996.
26.
ErvinT.J., ClarkJ.R., WeichselbaumR.R., FallonB.G., MillerD., FabianR.L., PosnerM.R., NorrisC.M., TuttleS.A., SchoenfeldD.A., PriceK.N., FreiEIII: An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol, 5: 10–20, 1987.
27.
VokesE.E., MoranW.J., MickR., WeichselbaumR.R., PanjeWR: Neoadjuvant and adjuvant methotrexate, cisplatin, and fluorouracil in multimodal therapy of head and neck cancer. J Clin Oncol, 7: 838–845, 1989.
